Hypofractionated stereotactic radiotherapy for oligometastases in the brain: A single-institution experience

Marcello Marchetti, Ida Milanesi, Chiara Falcone, Michela De Santis, Luisa Fumagalli, Lorenzo Brait, Livia Bianchi, Laura Fariselli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45% at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32% of the patients died from brain tumour progression. Actuarial overall survival was 75% at 3 months and 25% at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65%). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.

Original languageEnglish
Pages (from-to)393-399
Number of pages7
JournalNeurological Sciences
Volume32
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Radiotherapy
Brain
Survival
Neoplasm Metastasis
Brain Neoplasms
Therapeutics
Neoplasms

Keywords

  • Cerebral oligometastases
  • Hypofractionated stereotactic radiotherapy
  • Whole-brain radiotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Hypofractionated stereotactic radiotherapy for oligometastases in the brain : A single-institution experience. / Marchetti, Marcello; Milanesi, Ida; Falcone, Chiara; De Santis, Michela; Fumagalli, Luisa; Brait, Lorenzo; Bianchi, Livia; Fariselli, Laura.

In: Neurological Sciences, Vol. 32, No. 3, 06.2011, p. 393-399.

Research output: Contribution to journalArticle

Marchetti, Marcello ; Milanesi, Ida ; Falcone, Chiara ; De Santis, Michela ; Fumagalli, Luisa ; Brait, Lorenzo ; Bianchi, Livia ; Fariselli, Laura. / Hypofractionated stereotactic radiotherapy for oligometastases in the brain : A single-institution experience. In: Neurological Sciences. 2011 ; Vol. 32, No. 3. pp. 393-399.
@article{c2cb6397d2504d7dbde0815567ececd3,
title = "Hypofractionated stereotactic radiotherapy for oligometastases in the brain: A single-institution experience",
abstract = "The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45{\%} at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32{\%} of the patients died from brain tumour progression. Actuarial overall survival was 75{\%} at 3 months and 25{\%} at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65{\%}). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.",
keywords = "Cerebral oligometastases, Hypofractionated stereotactic radiotherapy, Whole-brain radiotherapy",
author = "Marcello Marchetti and Ida Milanesi and Chiara Falcone and {De Santis}, Michela and Luisa Fumagalli and Lorenzo Brait and Livia Bianchi and Laura Fariselli",
year = "2011",
month = "6",
doi = "10.1007/s10072-010-0473-4",
language = "English",
volume = "32",
pages = "393--399",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Hypofractionated stereotactic radiotherapy for oligometastases in the brain

T2 - A single-institution experience

AU - Marchetti, Marcello

AU - Milanesi, Ida

AU - Falcone, Chiara

AU - De Santis, Michela

AU - Fumagalli, Luisa

AU - Brait, Lorenzo

AU - Bianchi, Livia

AU - Fariselli, Laura

PY - 2011/6

Y1 - 2011/6

N2 - The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45% at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32% of the patients died from brain tumour progression. Actuarial overall survival was 75% at 3 months and 25% at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65%). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.

AB - The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45% at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32% of the patients died from brain tumour progression. Actuarial overall survival was 75% at 3 months and 25% at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65%). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.

KW - Cerebral oligometastases

KW - Hypofractionated stereotactic radiotherapy

KW - Whole-brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=79960175293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960175293&partnerID=8YFLogxK

U2 - 10.1007/s10072-010-0473-4

DO - 10.1007/s10072-010-0473-4

M3 - Article

C2 - 21234772

AN - SCOPUS:79960175293

VL - 32

SP - 393

EP - 399

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 3

ER -